# Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response

> **NCT01827930** · PHASE3 · TERMINATED · sponsor: **Institut Bergonié** · enrollment: 68 (actual)

## Conditions studied

- Leukemia, Myeloid, Chronic-Phase

## Interventions

- **DRUG:** Imatinib Mesylate 600 MG Oral Tablet
- **DRUG:** Imatinib Mesylate 400 MG Oral Tablet
- **DRUG:** Imatinib Mesylate

## Key facts

- **NCT ID:** NCT01827930
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-07
- **Primary completion:** 2017-01-01
- **Final completion:** 2017-01-01
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** Difficulties of enrolment of Patient
- **Last updated:** 2020-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827930, "Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01827930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*